#Myeloma Paper of the Day: Study of real world impact of bridging therapy prior to CAR T finds response showed no significant association with CRS, ICANS rates, or 3-month post-CAR-T response, and median PFS didn’t significantly differ based on response: pubmed.ncbi.nlm.nih.gov/38609386/.

Ciara Freeman speaking on clinical management of CAR-T therapy for older patients with multiple myeloma at the 17th International Workshop on Multiple #Myeloma in Miami, Day 2.

Paula Rodriguez-Otero speaking on developing bispecific antibodies for patients with multiple myeloma at the 17th International Workshop on Multiple #Myeloma in Miami, Day 2.

Yi Lin speaking on developments in CAR-T therapy for patients with multiple myeloma at the 17th International Workshop on Multiple #Myeloma in Miami, Day 2.

Hans Lee speaking in antibody drug conjugates for treatment of patients with multiple myeloma at the 17th International Workshop on Multiple #Myeloma in Miami, Day 2. MD Anderson Cancer Center

Nizar Bahlis presenting on elranatamab and resistance mechanisms to GPRC5D bispecifics in multiple myeloma at the 17th International Workshop on Multiple #Myeloma in Miami, Day 2.

Herman Einsele speaking on innovative CAR T designs and targets for patients with multiple myeloma at the 17th International Workshop on Multiple #Myeloma in Miami, Day 2.

Super grateful to Rahul Banerjee, MD, FACP for sharing some slides during preparation of this talk

Herman’s Einsele debating in favor of short duration of therapy with bispecifics for treatment of patients with multiple myeloma at the 17th International Workshop on Multiple #Myeloma in Miami, Day 2.

Ola Landgren debating in favor of long duration of therapy with bispecifics for treatment of patients with multiple myeloma at the 17th International Workshop on Multiple #Myeloma in Miami, Day 2.

An interesting debate- should and are we ready to risk stratify in #Myeloma 👍🏻Debate by Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 and Gareth Morgan at the 17th International Myeloma Workshop VJHemOnc C. Ola Landgren, M.D.

David Avigan debating in favor of CAR T-cells over bispecifics for treatment of patients with multiple myeloma at the 17th International Workshop on Multiple #Myeloma in Miami, Day 2.

Mark Raab debating in favor of bispecifics over CAR T-cells for treatment of patients with multiple myeloma at the 17th International Workshop on Multiple #Myeloma in Miami, Day 2.

Gareth Morgan debating against risk stratifying patients with multiple myeloma at the 17th International Workshop on Multiple #Myeloma in Miami, Day 2.

Saad Usmani debating in favor of risk stratification in multiple myeloma at the 17th International Workshop on Multiple #Myeloma in Miami, Day 2.

Sikander Ailawadhi speaking on targeting lipid rafts with CLR 131 (Iopofosine I-131) in multiple myeloma at the 17th International Workshop on Multiple #Myeloma in Miami, Day 2.

Mala Shanmugam speaking on targeting plasma cell metabolism in multiple myeloma at the 17th International Workshop on Multiple #Myeloma in Miami, Day 2.

Faith Davies speaking on targeting RAS with monobodies leveraging macropinocytosis in multiple myeloma at the 17th International Workshop on Multiple #Myeloma in Miami, Day 2.

Ryan Young speaking on novel regulators of IRF4 transcription factor in multiple myeloma at the 17th International Workshop on Multiple #Myeloma in Miami, Day 2.

Paula Rodriguez Otero speaking on alnuctumab and CELMoDs in multiple myeloma at the 17th International Workshop on Multiple #Myeloma in Miami, Day 2.